Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)
By Karen Loudon / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum Background The recent acquisition of ImmunoGen by...
Read More
Cartherics enters into Collaborative Research Agreement with TiCARos
By Karen Loudon / April 2, 2024
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More
Cartherics executes Option Agreement with The Ohio State University
By Karen Loudon / March 20, 2024
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or...
Read More
Cartherics: Leading the Charge in Immunotherapy for Solid Tumours
By Karen Loudon / March 19, 2024
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company's...
Read More
Teal Ribbon Day: Raising awareness for ovarian cancer
By Karen Loudon / February 28, 2024
Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed...
Read More
Cartherics to present and exhibit at Emergence 2024
By Karen Loudon / February 22, 2024
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at...
Read More
Cartherics’ CEO discusses the future of solid tumour therapy
By Karen Loudon / February 15, 2024
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the...
Read More
Ovarian cancer: Biotech company Cartherics to start human trials of new drug
By Karen Loudon / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More
Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy
By Karen Loudon / February 1, 2024
Melbourne, Australia, 1 February 2024 – Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the...
Read More
Cartherics to present at Australia Biologics Festival 2024
By Karen Loudon / January 23, 2024
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at...
Read More
Buoyant Life Sciences Sector Emerges Stronger
By Karen Loudon / December 18, 2023
BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in...
Read More
Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy
By Karen Loudon / November 28, 2023
As published in Drug Target Review Professor Alan Trounson, AO Dr Huimin Cao Dr Aleta Pupovac The suitability of NK...
Read More
Rearming the body to fight cancer
By Karen Loudon / November 15, 2023
Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian...
Read More
Importance of building Australia-China biotech collaborations
By Karen Loudon / November 1, 2023
China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation's international...
Read More
Life Science Success podcast with Prof. Alan Trounson
By Karen Loudon / October 20, 2023
Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this...
Read More
